米拉醋胺 | 76990-56-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 米拉醋胺
• 中文别名: 米那酰胺
• 英文名称: milacemide
• 英文别名: 2-n-pentylaminoacetamide；2-(n-pentylamino)acetamide；2-(pentylamino)acetamide
• CAS: 76990-56-2
• 化学式: C₇H₁₆N₂O
• mdl: MFCD00865293
• 分子量: 144.217
• InChiKey: GJNNXIYZWIZFRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  米拉醋胺 在 Tris-HCl buffer 、 monoamine oxidase-B (MAO-B) 作用下， 生成 甘氨酰胺 、 正戊酸
  参考文献：
  名称：

  Mechanism of inactivation of monoamine oxidase-B by the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide)

  摘要：

  The anticonvulsant agent milacemide (2-(n-pentylamino)acetamide) is known to inactivate monoamine oxidase-B (MAO-B). Various isotopically labeled analogues of milacemide are used to elucidate the mechanism of inactivation of MAO-B by this compound. The metabolites of the oxidation of milacemide by MAO-B (pentanoic acid, pentanal, and glycinamide) are shown not to be responsible for inactivation. MAO was inactivated with 2-(n-pentylamino)-acetamide (1a), 2-(n-pentylamino)[2,2-H-2(2)]acetamide (1b), and 2-([1,1-H-2(2)]-n-pentylamino)acetamide(1c). Compound 1b exhibited little or no isotope effect on inactivation (k(inact)/K(I)) and 1c showed an isotope effect of 4.55 on k(inact)/K(I). These compounds also were found to be excellent substrates for MAO-B; lb showed no isotope effect, but 1c exhibited an isotope effect of 4.53 on k(cat)/K(m). Incubation of MAO with 2-(n-pentylamino)[2-C-14] acetamide followed by dialysis under denaturing conditions resulted in the incorporation of 0.7 equiv of radioactivity per enzyme molecule. The same treatment with 2-([1-C-14]-n-pentylamino)acetamide led to the incorporation of 4 equiv of radioactivity into the enzyme. The excess radioactivity bound presumably arises from the [C-14]pentanal that is generated during turnover. In order to test this, MAO-B was incubated with [1-C-14]pentylamine under similar conditions and 5.9 equiv of radioactivity was incorporated into the denatured enzyme. Therefore, the entire molecule becomes attached to the enzyme during inactivation. By following changes in the flavin absorption spectrum during inactivation with milacemide, it was shown that the flavin becomes reduced; however, denaturation of the inactivation enzyme causes flavin reoxidation under conditions where radioactivity for 2-(n-pentylamino)[2-C-14]acetamide remains bound. This suggests that milacemide is oxidized during inactivation and the adduct results from attachment of milacemide to an amino acid residue, not to the flavin cofactor. Inactivation with 2-(11-C-14]-n-pentylamino)acetamide produced [C-14]pentanoic acid and [C-14]-pentylamine in the ratio of 92:8. Inactivation of MAO with 2-(n-pentylamino)[2-C-14]acetamide gave [C-14]glycinamide and [C-14]oxamic acid, further supporting oxidation reactions at both the pentyl side chain and the acetamido methylene. All of these results indicate that milacemide is oxidized at both the pentyl methylene and the acetamido methylene. Pentyl oxidation leads to inactivation, but it is not clear if acetamido methylene oxidation also leads to inactivation (Scheme I).

  DOI：

  10.1021/ja00065a001
• 作为产物：
  描述：

  1-氨基戊烷 、 草酸醛 生成 米拉醋胺
  参考文献：
  名称：

  RONCUCCI, R.;GILLET, G.;CORDI, A.;MARTENS, M.;ROBA, J.;NIEBES, P.;LAMBELL+

  摘要：

  DOI：

文献信息

• Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
  申请人：Graziano P. Michael

  公开号：US20050096307A1

  公开（公告）日：2005-05-05

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one lipid modulating agent; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种脂质调节剂；和(b)至少一种取代的噁唑烷酮或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖以及降低血浆中甾醇或5α-甾烷醇的水平。
• Combinations of substituted azetidinones and CB1 antagonists
  申请人：Veltri P. Enrico

  公开号：US20060069080A1

  公开（公告）日：2006-03-30

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB 1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种选择性CB1拮抗剂；和(b)至少一种取代的氮杂环丁烷或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖、代谢综合征以及降低血浆中的甾醇或5α-甾烷醇水平。
• [EN] SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS<br/>[FR] PIPÉRAZINES SUBSTITUÉES EN TANT QU'ANTAGONISTES DE CB1
  申请人：SCHERING CORP

  公开号：WO2009005645A1

  公开（公告）日：2009-01-08

  Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  化合物式(I)或其药用可接受的盐、溶剂合物或酯，可用于治疗由CB1受体介导的疾病或症状，如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（例如戒烟）、胃肠道疾病和心血管疾病。
• 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
  申请人：de Lera Ruiz Manuel

  公开号：US20070066644A1

  公开（公告）日：2007-03-22

  The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.

  本发明公开了化合物I的结构以及其药学上可接受的盐和溶剂化合物。该发明还涉及包括化合物I的药物组合物，并且其在治疗肥胖症、代谢综合征、糖尿病、肝脂肪病或非酒精性脂肪肝病中的用途。该发明还涉及将化合物I与其他治疗剂的组合物用于治疗肥胖症、代谢综合征、糖尿病、肝脂肪病或非酒精性脂肪肝病。
• Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
  申请人：Dean Anthony William

  公开号：US20080221185A1

  公开（公告）日：2008-09-11

  The invention provides a compound of formula (I) or a solvate thereof: wherein R 1 , R 2 , R 3, R 4 , R 5 , R 6 , and n are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

  该发明提供了化合物的结构式(I)或其溶剂化物：其中R1、R2、R3、R4、R5、R6和n如规范中所定义，并且这些化合物的用途。这些化合物抑制GlyT1转运体，在治疗某些神经系统和神经精神疾病，包括精神分裂症方面具有用处。